2022, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, pp. 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Liew, F, Talwar, S, Cross, A, Willett, B J, Scott, S, Logan, N, Siggins, M K, Swieboda, D, Sidhu, J K, Efstathiou, C, Moore, S C, Davis, C, Mohamed, N, Nunag, J, King, C, Thompson, A A R, Rowland-Jones, S L, Docherty, A B, Chalmers, J D, Ho, L-P, Horsley, A, Raman, B, Poinasamy, K, Marks, M, Kon, O M, Howard, L, Wootton, D G, Dunachie, S, Quint, J K, Evans, R A, Wain, L V, Fontanella, S, de Silva, T I, Ho, A, Harrison, E, Baillie, J K, Semple, M G, Brightling, C, Thwaites, R S, Turtle, L, Openshaw, P J M, ISARIC4C Investigators, Armour, C, Carson, G, Busby, J, Connolly, B, Cooper, J, Drain, S, Grieve, D, Hart, N, Harvey, M, Heaney, L G, Hughes, J, Jones, M G, Magee, N, McArdle, A, McGarvey, L, Mills, C, Mitchell, J, Peto, T, Powell, N, Rowland, M, Sharma, M & Siddiqui, S 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Horsley, A, Dark, P, Felton, T, et al, ISARIC4C Investigators & PHOSP-COVID Collaborative Group 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402
Investigators, ISARICC & Dark, P 2022, ' Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. ', Open Forum Infectious Diseases, vol. 9, no. 11, ofac531 . https://doi.org/10.1093/ofid/ofac531 2022, ' Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study ', Open forum infectious diseases, vol. 9, no. 11, ofac531 . https://doi.org/10.1093/ofid/ofac531 Open Forum Infectious Diseases Open Forum Infectious Diseases, 2022, 9 (11), ⟨10.1093/ofid/ofac531⟩
Lancet (London, England) investigators, ISARICC & Dark, P 2021, ' Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. ', Lancet (London, England), vol. 398, no. 10296, pp. 223-237 . https://doi.org/10.1016/S0140-6736(21)00799-6 The Lancet The Lancet, Elsevier, 2021, 398 (10296), pp.223-237. ⟨10.1016/S0140-6736(21)00799-6⟩ Drake, T, Riad, A M, Fairfield, C J, Egan, C, Knight, S, Pius, R, Hardwick, H E, Norman, L, Shaw, K, Mclean, K, Docherty, A B & Harrison, E M 2021, ' Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK : A prospective, multicentre cohort study ', The Lancet, vol. 398, no. 10296 . https://doi.org/10.1016/S0140-6736(21)00799-6
2021, ' Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study : a multicentre, prospective cohort study ', The Lancet Microbe . https://doi.org/10.1016/S2666-5247(21)00090-2 LANCET MICROBE The Lancet Microbe E365 E354 investigators, ISARICC & Dark, P 2021, ' Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. ', The Lancet. Microbe, vol. 2, no. 8, pp. e354-e365 . https://doi.org/10.1016/S2666-5247(21)00090-2 The Lancet. Microbe